NCT05958134Completed
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL: Multicenter Retrospective Study (Real World Evidence - RWE)
Source: ClinicalTrials.gov · Last updated 23 May 2025
Brief summary (registry, in English)
National, multicenter, non-randomized, retrospective observational study (Real World Evidence-RWE) to analyze the epidemiological profile of diffuse large B cell lymphoma, clinical management, treatment in molecular subgroups, progression profile and patient survival outcomes enrolled and treated within the last 6 years (2017 to 2022), in national cancer reference centers.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 600 (actual)
- First submitted
- 4 Jul 2023
- Start date
- 15 Jul 2023
- Primary completion date
- 6 Jun 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT05958134
What you commit to
- Study type: Observational
- Participants enrolled: 600
- From 15 Jul 2023 to the primary completion date, 6 Jun 2024
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No medical record of the molecular subgroup classification;
- Diagnosis of diffuse large B-cell lymphoma, confirmed in the year 2016;
- Patients diagnosed with Transformed Lymphomas.
Who the study is looking for
- Male and female;
- Age above 18 years old;
- Diagnosis of diffuse large B-cell lymphoma (DLBCL) and high-grade non-Hodgkin B-cell lymphoma at all stagings;
- Lymphoma classified for the cell of origin (GCB - Germinal Center B-Cell lymphoma, and non-germinal center);
- Having first life of treatment information available in institutional medical record;
- Having survival data available in institutional medical record.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Belo Horizonte | Brazil | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Recife | Brazil | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Salvador | Brazil | Unknown status |
| Research Site Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.